Skip to main content

Retraction Note: Dissecting the role of novel EZH2 inhibitors in primary glioblastoma cell cultures: effects on proliferation, epithelialmesenchymal transition, migration, and on the pro-inflammatory phenotype

The Original Article was published on 02 December 2019

Retraction Note : Clinical Epigenetics (2019) 11:173 https://doi.org/10.1186/s13148-019-0763-5

The Editors-in-Chief have retracted this article. After publication, concerns were raised regarding image similarities in the western blot and invasion assay data presented in the figures. Specifically:

Fig. 5a H3K27me3 GL1 lanes 2 and 3 appear highly similar.

Fig. 5b H3K27me3 lane 1 appears highly similar to lane 5.

Fig. 7a and 9a appear to share the same beta-actin control blot.

Fig. 9b U-87 MC4040 and MC4041 images appear to originate from the same sample, although the stated treatments are different.

The authors have stated that the overlapping images in Fig. 9b were included by mistake. They have also provided partial raw data to address the western blot concerns; however, further checks by the Publisher have found that a number of western blot images presented in the article don't accurately represent the original data. The Editors-in-Chief therefore no longer have confidence in the presented data.

Susanna Scarpa does not agree to this retraction. Giulia Stazi, Rossella Fioravanti, Manuela Sabatino, Rino Ragno, Samanta Taurone, Marcella Nebbioso, Raffaella Carletti, Marco Artico, Sergio Valente and Antonello Mai have not responded to any correspondence from the publisher about this retraction. The publisher has not been able to obtain current email addresses for Ludovica Taglieri, Alice Nicolai, Annalisa Romanelli and Stefania Morrone.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Sergio Valente, Susanna Scarpa or Antonello Mai.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stazi, G., Taglieri, L., Nicolai, A. et al. Retraction Note: Dissecting the role of novel EZH2 inhibitors in primary glioblastoma cell cultures: effects on proliferation, epithelialmesenchymal transition, migration, and on the pro-inflammatory phenotype. Clin Epigenet 15, 179 (2023). https://doi.org/10.1186/s13148-023-01595-6

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s13148-023-01595-6